Genmab (GMAB) Reports 19% Revenue Growth to $3.7B in 2025 Driven by Proprietary Medicine Sales

Genmab (NASDAQ:GMAB) is one of the best NASDAQ growth stocks to buy for the next 2 years. On February 17, Genmab reported that its total revenue grew by 19% in 2025 to a total $3.7 billion. This growth was fueled by a 54% surge in sales of its proprietary medicines, most notably Abkinley, which generated $468 million, which was a 67% year-over-year increase. The company also benefited from the continued success of its royalty portfolio, particularly Darzalex, which is projected to reach net sales of up to $16.4 billion in 2026.

The company strategically expanded throughout the year, highlighted by the acquisition of ProfoundBio and its promising late-stage asset, Rina-S. Genmab particularly expanded its clinical pipeline with three new Phase 3 trials and secured FDA approval for Abkinley in second-line follicular lymphoma.

However, the company faced a hurdle with the Phase 3 EPCOR DLBCL-1 trial: while Genmab (NASDAQ:GMAB) met its progression-free survival goals, it missed statistical significance for overall survival, leading to ongoing discussions with regulatory authorities to address trial biases like COVID-19 and the impact of subsequent therapies.

Genmab (NASDAQ:GMAB) is a biotechnology company that develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark.

While we acknowledge the potential of GMAB as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.